https://european-biotechnology.net/wp-content/uploads/2026/01/sangharsh-lohakare-8o_LkMpo8ug-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-27 15:52:432026-01-27 15:52:43After decades in biotech, Gimv draws a line under new life sciences deals
https://european-biotechnology.net/wp-content/uploads/2026/01/Adv_11_22_ABA_Austria.png540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-27 14:09:582026-01-27 14:09:58For €170 million: Vienna gives AI and life sciences a new home
https://european-biotechnology.net/wp-content/uploads/2026/01/Genmab-US-Office-1-Andrei-Jackamets-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-27 05:05:062026-01-27 05:05:06Genmab pauses enrollment in early ADC trial acquired from ProfoundBio
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-abdoo-35143804-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-23 15:23:072026-01-23 15:23:07London-based Ellipses licenses another oncologic asset from Chinese pharma
https://european-biotechnology.net/wp-content/uploads/2026/01/francesco-gallarotti-ruQHpukrN7c-unsplash.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-21 18:26:422026-01-21 18:26:42Oxford-based cancer vaccine company Infinitopes closes $35 million seed round
https://european-biotechnology.net/wp-content/uploads/2026/01/JPM-Week-SF-Bay-Bridge-1030x773-1.jpg7731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-21 15:39:022026-01-21 15:39:02A changing playing field: Observations of the 2026 JP Morgan Healthcare Conference from a European perspective
